These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23126597)

  • 1. Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B.
    Grogan PM; Alvarez MV; Jones L
    Headache; 2013 Jan; 53(1):126-136. PubMed ID: 23126597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imploding and exploding migraine headaches: comparison of methods to diagnose pain directionality.
    Files JA; Schwedt TJ; Mayer AP; David PS; Vargas BB; Chang YH; Hunt M; Patel S; Ko MG; Tozer BS; Burstein R; Dodick DW
    Headache; 2014 Jun; 54(6):1010-8. PubMed ID: 24527766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migraine prophylaxis with botulinum toxin A is associated with perception of headache.
    Burstein R; Dodick D; Silberstein S
    Toxicon; 2009 Oct; 54(5):624-7. PubMed ID: 19344670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.
    Jakubowski M; McAllister PJ; Bajwa ZH; Ward TN; Smith P; Burstein R
    Pain; 2006 Dec; 125(3):286-295. PubMed ID: 17069972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting migraine responsiveness to botulinum toxin type A injections.
    Kim CC; Bogart MM; Wee SA; Burstein R; Arndt KA; Dover JS
    Arch Dermatol; 2010 Feb; 146(2):159-63. PubMed ID: 20157026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.
    Chen TY; Garza I; Dodick DW; Robertson CE
    Headache; 2018 Jul; 58(7):973-985. PubMed ID: 29762872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
    Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
    Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.
    Binder WJ; Brin MF; Blitzer A; Schoenrock LD; Pogoda JM
    Otolaryngol Head Neck Surg; 2000 Dec; 123(6):669-76. PubMed ID: 11112955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing disturbing migraine aura with lamotrigine: an open study.
    Pascual J; Caminero AB; Mateos V; Roig C; Leira R; García-Moncó C; Laínez MJ
    Headache; 2004; 44(10):1024-8. PubMed ID: 15546267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism.
    Wahl A; Praz F; Tai T; Findling O; Walpoth N; Nedeltchev K; Schwerzmann M; Windecker S; Mattle HP; Meier B
    Heart; 2010 Jun; 96(12):967-73. PubMed ID: 20538672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of botulinum toxin type B for migraine and tension headaches.
    Fadeyi MO; Adams QM
    Am J Health Syst Pharm; 2002 Oct; 59(19):1860-2. PubMed ID: 12374073
    [No Abstract]   [Full Text] [Related]  

  • 13. Botox treatment for migraine and chronic daily headache in adolescents.
    Chan VW; McCabe EJ; MacGregor DL
    J Neurosci Nurs; 2009 Oct; 41(5):235-43. PubMed ID: 19835236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Mitsikostas DD
    J Headache Pain; 2016 Dec; 17(1):84. PubMed ID: 27640152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.
    Jackson JL; Kuriyama A; Hayashino Y
    JAMA; 2012 Apr; 307(16):1736-45. PubMed ID: 22535858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onabotulinum toxin a for the treatment of headache in service members with a history of mild traumatic brain injury: a cohort study.
    Yerry JA; Kuehn D; Finkel AG
    Headache; 2015 Mar; 55(3):395-406. PubMed ID: 25644249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Women's issues of migraine in tertiary care.
    Kelman L
    Headache; 2004 Jan; 44(1):2-7. PubMed ID: 14979877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onabotulinumtoxin A (BOTOX®) for ProphylaCTIC Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis.
    Shah S; Calderon MD; Wu W; Grant J; Rinehart J
    J Child Neurol; 2018 Aug; 33(9):580-586. PubMed ID: 29877131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
    Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
    Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.